Hypobetalipoproteinemia (HBL) is defined by very low levels (<5th percentile) of total apoB and/or low-density lipoprotein (LDL) cholesterol in plasma (2)

Apolipoprotein B
ApoB-48 and ApoB-100 produced from same gene
ApoB-48 is produced in enterocytes - constituent of chylomicrons
ApoB-100 is produced in hepatocytes - constituent of VLDL and LDL

Primary - inability to produce chylomicrons in enterocytes
Chylomicron retention disease
Familial hypobetalipoproteinaemia (FHBL)

Secondary - intestinal fat malabsorption
Chronic pancreatitis
Severe liver disease (eg HCV)
Strict veganism

Microsomal triglyceride transfer protein (MTP)
Chylomicron retention disease
SARA2 gene mutations
FHBL (2/3)
(i) premature stop codon specifying mutations of APOB (chromosome 2)
(ii) ANGPTL3 (chromosome 3p21)

(iii) FHBL linked neither to APOB nor to the chromosome 3p21.

Abetalipoproteinaemia / chylomicron retention disease
FTT, anaemia, acanthocytosis, ataxia (similar to Friedreich’s ataxia), retinitis pigmentosa
Heterozygous FHBL
Largely asymptomatic, Low LDL / ApoB
Express ~25% of normal ApoB-100 levels
May have chronic diarrhoea due to partial fat malabsorption
NAFLD (in those with ApoB mutations only) (1)
Can progress to cirrhosis (3)
Homozygous FHBL
Similar to abetalipoproteinaemia, but generally less severe
Severe fat malabsorption
Fat soluble vitamin deficiencies

Fat malabsorption, when present, is treated by limiting the intake of fats containing longchain fatty acids and substituting medium-chain triglycerides to furnish fat calories. Fat-soluble vitamins may need to be given as well. These are available in injectable forms or as water-soluble emulsions. The fatty liver has to date not been treated, because it is not clear how and whether this needs to be done. More studies are needed (2)
Diet and exercise / weight loss improve LFTs and NAFLD

Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-ShareAlike 3.0 License